Fundraising Fox
Syncromune
Fort Lauderdale, US · Founded 2020 · Delaware corporation
Find your way into Syncromune
Sign up to see every warm intro you have to Syncromune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Syncromune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Syncromune develops SYNC-T, an investigational in situ personalized combination immunotherapy platform designed to treat metastatic solid tumors by synchronizing patient-specific tumor antigens with immune modulatory biologics. The company's lead candidate, SV-102, is in Phase 2 clinical trials for metastatic castration-resistant prostate cancer.
Founders & leadership
JG
Joseph GerardiExecutive
SD
Stephen DaleChief Medical OfficerStephen Dale is Chief Medical Officer and Head of R&D at Syncromune, where he oversees clinical development and regulatory strategy. He brings more than 23 years of oncology drug development experience across solid and hematologic malignancies, with involvement in clinical programs from early development through regulatory approval, and holds a license to practice medicine with the UK General Medical Council.
KM
AG
Agustin GagoChief Business OfficerAgustin Gago brings over three decades of experience in sales, marketing, product development, and operations across pharmaceuticals, medical devices, and capital equipment, with specialization in oncology, surgery, cardiology, and radiology. He has held progressive leadership roles managing relationships with healthcare providers, suppliers, and clinical organizations.
EH
Eamonn HobbsNamed on SEC filing
Board
JL
Jeffrey L. ClelandBoard director
DG
Douglas G. WatsonBoard director
JC
Joseph C. MaroonBoard director
NS
Norman SchwartzBoard director
Reported raises · per SEC filings
Form D private placements$159M disclosed across 2 rounds · 2022–2024
▶$144.8MraisedMay 2026 · 77 investors · BiotechnologyRule 506(b)
▶$144.8MraisedMay 2026 · 77 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph GerardiExecutive Officer
- Jeffrey L. ClelandDirector
- Douglas G. WatsonDirector
- Joseph C. MaroonDirector
- Stephen DaleExecutive Officer
- Norman SchwartzDirector
- Charles J. LinkExecutive Officer, Director
- Eamonn HobbsExecutive Officer, Director
- Kerri-Ann MillarExecutive Officer
- Agustin GagoExecutive Officer
- Offering amount
- $144.8M
- Amount sold
- $144.8M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.2MraisedOct 2023 · 44 investors · Other Health CareRule 506(b)
▶$14.2MraisedOct 2023 · 44 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joseph GerardiExecutive Officer
- Norman SchwartzDirector
- EAMONN HOBBSExecutive Officer, Director
- AGUSTIN GAGOExecutive Officer
- Douglas G. WatsonDirector
- Jeffrey L. ClelandDirector
- Charles J. LinkExecutive Officer, Director
- Joseph C. MaroonDirector
- Offering amount
- $20M
- Amount sold
- $14.2M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Primmune TherapeuticsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
AdaptimmuneAdaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
Immunomic TherapeuticsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies working in the same space as Syncromune.
In the news
Frequently asked questions
- What does Syncromune do?
- Syncromune develops SYNC-T, an investigational in situ personalized combination immunotherapy platform designed to treat metastatic solid tumors by synchronizing patient-specific tumor antigens with immune modulatory biologics. The company's lead candidate, SV-102, is in Phase 2 clinical trials for metastatic castration-resistant prostate cancer.
- How much funding has Syncromune raised?
- Syncromune has disclosed $159M raised across 2 rounds.
- Where is Syncromune headquartered?
- Syncromune is headquartered in Fort Lauderdale, US.